LIPO-202 is an injectable pharmaceutical designed to produce aesthetic reduction of subcutaneous abdominal fat. Lithera president and CEO George Mahaffey said, "Following our recent Series C financing, Lithera
As per the agreement, Receptos will lead a Phase 2 clinical study to demonstrate proof-of-concept in Eosinophilic Esophagitis (EoE), an indication designated as an Orphan Disease by the
The company has developed NT0202, leveraging its extended-release technology, as a treatment to attention deficit hyperactivity disorder (ADHD) and is requesting for manufacturing and marketing approval of the
MK-8931 is an oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor. Under the agreement, Luminex will leverage xMAP technology in developing the candidate device to measure
Dymista is indicated for patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief. The new nasal spray
Dr Ramachandra served as senior vice president, R&D, regulatory and medical affairs, and chief scientific officer of Hospira. Prior to Hospira, he served as vice president and oncology
This is an extention to the initial collaboration between scientists on the Florida campus of TSRI and Envoy Therapeutics in 2010 that led to several breakthroughs in identifying
The broad spectrum, oral nucleotide analog lipid-conjugate, CMX001, works by blocking the replication of double-stranded DNA (dsDNA) viruses. The company previously completed Phase II clinical development of CMX001
NC-stat DPNCheck is a quantitative point-of-care test used to detect diabetic neuropathy at an early stage. Handok expects to use both direct and indirect sales channels to promote
The company has submitted a biologics license application (BLA) to the US regulatory body based on the data from registrational Phase III hemophilia A study called A-LONG. Biogen
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.